Loading...
XMADALM
Market cap1.82bUSD
Dec 20, Last price  
8.16EUR
1D
0.00%
1Q
-2.74%
Jan 2017
-43.51%
IPO
-44.42%
Name

Almirall SA

Chart & Performance

D1W1MN
XMAD:ALM chart
P/E
—
P/S
1.94
EPS
—
Div Yield, %
0.15%
Shrs. gr., 5y
0.95%
Rev. gr., 5y
3.50%
Revenues
895m
+3.62%
736,132,000792,542,000853,084,000902,800,000925,500,000882,400,000768,418,000715,232,000747,628,000819,040,000689,225,000764,361,000639,381,000756,934,000855,339,0001,614,854,000827,195,000863,248,000894,516,000
Net income
-38m
L
117,725,000147,250,000131,206,000136,100,000151,500,000118,600,00084,166,00076,291,000-33,717,000448,429,000131,826,00075,479,000-303,961,00077,674,000105,909,00074,280,000-40,859,0004,281,000-38,474,000
CFO
93m
-39.73%
141,570,000164,089,000179,031,000233,100,000261,600,000174,600,000100,140,000112,754,00067,114,000646,935,000170,884,000105,056,0006,094,000143,209,000276,146,000164,764,000233,852,000155,102,00093,485,000
Dividend
May 17, 20240.184 EUR/sh
Earnings
May 09, 2025

Profile

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
URL
https://www.almirall.es/
IPO date
Apr 19, 2007
Employees
1,876
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
894,516
3.62%
863,248
4.36%
827,195
-48.78%
Cost of revenue
503,450
289,175
252,661
Unusual Expense (Income)
NOPBT
391,066
574,073
574,534
NOPBT Margin
43.72%
66.50%
69.46%
Operating Taxes
21,283
26,746
31,774
Tax Rate
5.44%
4.66%
5.53%
NOPAT
369,783
547,327
542,760
Net income
(38,474)
-998.72%
4,281
-110.48%
(40,859)
-155.01%
Dividends
(2,592)
(12,419)
(11,746)
Dividend yield
0.16%
0.76%
0.58%
Proceeds from repurchase of equity
197,924
BB yield
-11.92%
Debt
Debt current
17,210
16,714
18,445
Long-term debt
429,847
426,197
398,100
Deferred revenue
Other long-term liabilities
102,554
89,947
121,200
Net debt
36,089
159,433
128,657
Cash flow
Cash from operating activities
93,485
155,102
233,852
CAPEX
(33,499)
(116,480)
(71,152)
Cash from investing activities
(122,559)
(68,543)
(57,255)
Cash from financing activities
168,205
(45,122)
(134,878)
FCF
368,429
505,413
611,884
Balance
Cash
388,090
248,823
207,386
Long term investments
22,878
34,655
80,502
Excess cash
366,242
240,316
246,528
Stockholders' equity
920,392
1,008,233
951,526
Invested Capital
1,602,958
1,545,579
1,537,345
ROIC
23.49%
35.51%
32.92%
ROCE
19.16%
30.81%
30.89%
EV
Common stock shares outstanding
196,992
180,758
178,910
Price
8.43
-6.75%
9.04
-20.00%
11.30
3.48%
Market cap
1,660,643
1.63%
1,634,052
-19.17%
2,021,683
-2.01%
EV
1,696,732
1,793,485
2,150,340
EBITDA
515,382
694,709
694,471
EV/EBITDA
3.29
2.58
3.10
Interest
15,388
7,439
12,972
Interest/NOPBT
3.93%
1.30%
2.26%